Literature DB >> 2493981

Effect of dietary palm oils on mammary carcinogenesis in female rats induced by 7,12-dimethylbenz(a)anthracene.

K Sundram1, H T Khor, A S Ong, R Pathmanathan.   

Abstract

Female Sprague-Dawley rats, 50 days of age, were treated with a single dose of 5 mg of 7,12-dimethylbenz(a)anthracene intragastrically. 3 days after carcinogen treatment, the rats were put on semisynthetic diets containing 20% by weight of corn oil (CO), soybean oil (SBO), crude palm oil (CPO), refined, bleached, deodorized palm oil (RBD PO) and metabisulfite-treated palm oil (MCPO) for 5 months. During the course of experiments, rats fed on different dietary fats had similar rate of growth. Rats fed 20% CO or SBO diet have higher tumor incidence than rats fed on palm oil (PO) diets; however differences of mean tumor latency periods among the groups were not statistically significant. At autopsy, rats fed on high CO or SBO diets had significantly more tumors than rats fed on the three PO diets. Our results showed that high PO diets did not promote chemically induced mammary tumorigenesis in female rats when compared to high CO or SBO diets. CO and SBO differ greatly from the palm oils in their contents of tocopherols, tocotrienols, and carotenes. But further experiments would be required to determine whether the observed differences in tumor incidence and tumor numbers were due to the differences in these minor components or due to the unique triglyceride structure of the palm oils. Analysis of the fatty acid profiles of plasma total lipids of tumor-bearing rats and of the tumor total lipids showed that, with the exception of arachidonic acid, the fatty acid profiles reflect the nature of the dietary fats. At autopsy, there were no differences in the plasma total cholesterol contents among rats fed on different dietary fats, but rats fed on palm oil diets had a significantly higher plasma triglyceride level than that of rats fed CO or SBO diets. As for the tumor lipids, there were no significant differences in the triglyceride, diglyceride, and phospholipid levels when the CO or SBO groups were compared to the palm oil groups.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2493981

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Tocotrienols and breast cancer: the evidence to date.

Authors:  Kalanithi Nesaretnam; Puvaneswari Meganathan; Sheela Devi Veerasenan; Kanga Rani Selvaduray
Journal:  Genes Nutr       Date:  2011-04-24       Impact factor: 5.523

2.  {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.

Authors:  Ajaikumar B Kunnumakkara; Bokyung Sung; Jayaraj Ravindran; Parmeswaran Diagaradjane; Amit Deorukhkar; Sanjit Dey; Cemile Koca; Vivek R Yadav; Zhimin Tong; Juri G Gelovani; Sushovan Guha; Sunil Krishnan; Bharat B Aggarwal
Journal:  Cancer Res       Date:  2010-09-23       Impact factor: 12.701

3.  Tocotrienols fight cancer by targeting multiple cell signaling pathways.

Authors:  Ramaswamy Kannappan; Subash C Gupta; Ji Hye Kim; Bharat B Aggarwal
Journal:  Genes Nutr       Date:  2011-04-09       Impact factor: 5.523

4.  γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent.

Authors:  Peramaiyan Rajendran; Feng Li; Kanjoormana Aryan Manu; Muthu K Shanmugam; Ser Yue Loo; Alan Prem Kumar; Gautam Sethi
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 5.  Specificity of the suppression of metastatic phenotype by tyrosine and phenylalanine restriction.

Authors:  C A Elstad; G G Meadows; R M Abdallah
Journal:  Clin Exp Metastasis       Date:  1990 Sep-Oct       Impact factor: 5.150

Review 6.  Tocotrienols: Vitamin E beyond tocopherols.

Authors:  Chandan K Sen; Savita Khanna; Sashwati Roy
Journal:  Life Sci       Date:  2006-02-03       Impact factor: 5.037

7.  Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status.

Authors:  K Nesaretnam; R Stephen; R Dils; P Darbre
Journal:  Lipids       Date:  1998-05       Impact factor: 1.880

Review 8.  Effects of exogenous lipids on cancer and cancer chemotherapy. Implications for treatment.

Authors:  C P Burns; B A Wagner
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

Review 9.  Tocotrienols: the emerging face of natural vitamin E.

Authors:  Chandan K Sen; Savita Khanna; Cameron Rink; Sashwati Roy
Journal:  Vitam Horm       Date:  2007       Impact factor: 3.421

Review 10.  Tocotrienols in health and disease: the other half of the natural vitamin E family.

Authors:  Chandan K Sen; Savita Khanna; Sashwati Roy
Journal:  Mol Aspects Med       Date:  2007-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.